AbbVie (ABBV) Stock: Rises as RINVOQ Wins EU Approval for Severe Hair Loss

TLDR AbbVie stock gained 1.17% to $266.27 after RINVOQ secured major EU approval. The approval covers adults and adolescents aged 12 and older with severe AA. Phase 3 studies showed significant scalp hair regrowth after 24 weeks of use. Both RINVOQ doses met key efficacy goals across two controlled Phase 3 studies. The decision expands [...]

The post AbbVie (ABBV) Stock: Rises as RINVOQ Wins EU Approval for Severe Hair Loss appeared first on Blockonomi.